سعر اتوميتافلوزين Atometaflozine‏ 12.5/500مجم 30 قرص 2026

Empagliflozin + Metformin 12.5 mg / 500 mg film-coated tablet, pack of 30 film-coated tablets (Atos Pharma).

• Severe renal impairment (eGFR <30 mL/min/1.73 m2); acute or chronic metabolic acidosis including diabetic ketoacidosis; hypersensitivity to empagliflozin, metformin or any excipient.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: metformin-associated lactic acidosis (risk factors: renal impairment, certain drugs, age >=65, iodinated contrast, surgery, hypoxia, excess alcohol, hepatic impairment); discontinue and hospitalize if suspected.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Ketoacidosis, volume depletion, urosepsis/pyelonephritis, Fournier's gangrene, genital mycotic infections, hypoglycaemia with insulin or secretagogues, and vitamin B12 deficiency (metformin).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Carbonic anhydrase inhibitors, drugs reducing metformin clearance (e.g. ranolazine, dolutegravir, cimetidine), alcohol, iodinated contrastMay increase lactic acidosis risk; monitor or temporarily stop as per label.DailyMed (U.S. National Library of Medicine)

• Not recommended during the second and third trimesters (empagliflozin animal renal findings); limited data insufficient to determine risk.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Not recommended while breastfeeding (potential effect of empagliflozin on the developing kidney).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Empagliflozin: Inhibits SGLT2 in the proximal renal tubule, reducing renal reabsorption of filtered glucose and lowering the renal threshold for glucose, thereby increasing urinary glucose excretion (US label).
• Metformin: Decreases hepatic glucose production, decreases intestinal glucose absorption and improves insulin sensitivity by increasing peripheral glucose uptake and utilization; insulin secretion remains unchanged (US label).